🔴 Sellas Life Sciences is trading 5% down today as investors await preliminary REGAL results

Sellas Life Sciences is trading at $9.19, down 5.06%, as investors await REGAL trial results.

• The decline appears to extend the pullback after the October 28 announcement that the Phase 3 REGAL trial reached its 80th event and entered final analysis.
• The milestone did not disclose whether treatment improved survival; preliminary results are expected this quarter.
• No distinct November 2 company announcement surfaced; broader markets were higher, so market-wide weakness does not explain the decline.